The discovery of cell-free DNA (cfDNA) dates back to 1948, when Mandel and Metais found it in the sera of cancer patients [1]. Later, Tan et al. observed a correlation with the cfDNA concentration and development of autoimmune disease in 1966 [2]. Leon et al. started to use cfDNA in tumor diagnosis in 1977, but unfortunately due to the molecular biological technical possibilities they were not very successful [3]. A breakthrough occurred in 1997, when Dennis Lo started to detect RhD and fetal sex in maternal plasma by using real-time PCR [4]. The real spread of non-invasive detection of fetal genetic diseases started in 2011, when massive parallel sequencing was introduced [5]. Nowadays, about half of the prenatal genetic examination is performed by so-called non-invasive prenatal testing (NIPT).

The clinical application of cfDNA has been rapidly growing in the field of oncology; it gives the possibility of the early detection of cancer in different body fluids via liquid biopsy. Cancer type specific molecular signatures could be detected in very early stages of tumor development. Drug resistance is a burning problem during the treatment of patients. In addition to the mutation screening methylation profile, there has been increasing interest in the use of surrogate markers for follow up in cancer patients with metastasis [6].

Alongside the increasing application of cfDNA, interest is growing in the utilization of cell-free RNAs (cfRNAs), such as microRNA (miRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA), in different types of diseases [7]. Their concentrations are surprisingly stable in sera or plasma due to their encapsulation into extracellular vesicles (microvesicles, exosomes). From these, it seems that exosomes could tremendously improve the current diagnostic arsenal. While the exact nucleic acid, protein, and lipid contents of these small microvesicles are still under investigation, it has been shown that exosomes play important roles in intracellular, cell-cell, and cell-tissue communication [8].

miRNAs are important small non-coding RNAs that are 18–25 base pairs (bp) in size. They are able to bind to proteins such as Argonaute-2, HDL, and LDL, and a single miRNA can regulate the expression of several of genes [9,10]. Disturbances in the regulation of key miRNAs can have tremendous effects on gene expression and on normal and pathophysiological processes [6].

LncRNAs, which are >200 bp in size, are new players in this field. It seems that they have an even higher diagnostic and prognostic value due to their specific expression in different type of tissues and diseases; importantly, they are very stable in different conditions [11]. It has been shown that they are useful in the diagnosis of different types of cancer and cardiovascular diseases [11].

CircRNAs are newly discovered non-coding RNAs with the size of couple of thousands base pairs. They have a closed circular structure with a function of tumor suppressor or promoter in several types of cancer. They can be used as biomarkers or therapeutic targets [12]. They can also serve as sponges to inhibit miRNAs [13]. Altered expression of circRNAs has been reported recently [14,15].

This exciting field of research is expected to produce a lot of diagnostic and new generation treatment possibilities. The high interest in this topic shows in the enormous quantity of published papers in different journals. Coincidently, there was a Special Issue in the Journal of Biotechnology earlier this year dealing with this subject. Researchers from Central-Eastern Europe showed their work on cell-free nucleic acids [16–19].
This Special Issue contains eight original research studies [20–27], and five review papers [28–32]; the diversity of the papers demonstrates how many different topics are covered by cell-free nucleic acid research.

Three research papers deal with the prenatal application of cfDNA. Pös et al.’s “Identification of Structural Variation from NGS-Based Non-Invasive Prenatal Testing” shows that copy number variants (CNVs) are important subjects for the study of human genome variations, as CNVs can contribute to population diversity and human genetic diseases [20]. Additionally, CNVs are useful in NIPT, as they are a source of population specific data [20].

Gazdarica et al. studied the reliability of NIPT, which depends on the accurate estimation of fetal fraction [21]. They propose several improvements in fetal fraction estimation to get more reliable results [21].

In their other work, Gazdarica et al. demonstrated a new, more stable prediction method for NIPT that provides highly divergent inter-sample coverage [22].

Preeclampsia is a mysterious disease—despite intensive research, we still do not know the exact details of its development. It seems that cell-free nucleic acids could serve as biomarkers for the early detection of this disease. Hromadnikova et al. measured exosomal C19MC microRNAs and found them to be important in the detection of pregnancy associated complications [23].

Improving the success rate of vitro fertilization (IVF) and embryo transfer (ET) is an important goal. Timofeeva et al. reported a very interesting application of small non-coding RNAs to improve the efficiency of embryo transfer (ET) by measuring embryo-specific sncRNAs in the culture media [24].

Ovarian cancer is one of the leading serious malignancies among women, with high incidence of mortality; the introduction of new diagnostic markers could help in its early detection and treatment. Penyige et al. showed their results from using the NanoString technique to get information on the expression of 800 miRNAs in one run, and they checked the reliability of the obtained results by conventional real-time PCR [25].

Epigenetic regulation is very important during the development of diseases and drug resistance. Dvorská et al. found that methylation changes are important signs during ovarian cancer development and that the CDH1 gene is a potential candidate for being a non-invasive biomarker in the diagnosis of ovarian cancer [26].

We received interesting reviews on the application of cell-free nucleic acids. Zubor at al. reviewed the deficits of mammography and demonstrated the potential of non-invasive diagnostic testing using circulating miRNA profiles [27].

Exosomes are important in the transfer of genetic information. Konečná et al. discussed the current knowledge on not only exosome-associated DNA but on vesicles-associated DNA, and their role in pregnancy-related complications [28]. It seems that a major obstacle is the lack of a standardized technique for exosomes isolation and measurement [28].

Kubiritova et al. summarized what we know about cell-free nucleic acids in inflammatory bowel disease (IBD). Despite extensive research, the etiology and exact pathogenesis are still unclear, although similar to the cfNAs (cell-free ribonucleic acids) observed in other autoimmune diseases, it seems to be relevant in IBD. The authors collected literature on cfDNA and cfRNA and on exosomes and neutrophil extracellular traps and their association with IBD. Based on the information from the reported literature, they propose the use of cfNAs (cell-free nucleic acids) in the management of IBD as biomarkers and as a potential therapeutic target [29].

Dvorska et al. reviewed the utility of liquid biopsy as a tool for the differentiation of leiomyomas and sarcomas of corpus uteri [30]. They collected the most important knowledge of mesenchymal uterine tumors and showed the benefits of liquid biopsy [30].

Microchimerism has also recently become a hot topic too. Andrikovics et al. discuss microchimerism in the context of various forms of transplantation and transplantation-related advanced therapies, and they show the available cfNA (cell-free nucleic acid) markers and detection platforms [31].
There is only one article in this issue related to animal studies. Janovičová et al. showed that sex, age, and bodyweight are not determinants of cfDNA variability in healthy mice, and they call attention to the importance of understanding the production and cleavage of cfDNA [32].

I would like express my thanks to all of the authors for their valuable contributions to this Special Issue, and would also like to express my gratitude to the editorial staff members and anonymous reviewers who helped to improve the quality of the submitted manuscripts. I hope readers will find this issue to be both interesting and useful.

Conflicts of Interest: The author declares no conflict of interest.

References

1. Mandel, P.; Metais, P. Les acides nucléiques du plasma sanguine chez l’homme. CR Seances Soc. Biol. Fil. 1948, 142, 241–243.
2. Tan, E.M.; Schur, P.H.; Carr, R.I.; Kunkel, H.G. Deoxyribonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J. Clin. Investig. 1966, 45, 1732–1740. [CrossRef] [PubMed]
3. Leon, S.A.; Shapiro, B.; Sklaroff, D.M.; Yaros, M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977, 37, 646–650. [PubMed]
4. Lo, D.Y.M.; Corbetta, N.; Chamberlain, P.F.; Rai, V.; Sargent, I.L.; Redman, C.W.; Wainscoat, J.S. Presence of fetal DNA in maternal plasma and serum. Lancet 1997, 350, 485–487. [CrossRef]
5. Palomaki, G.E.; Kloza, E.M.; Lambert-Messerlian, G.M.; Haddow, J.E.; Neveux, L.M.; Ehrich, M.; van den Boom, D.; Bombard, A.T.; Deciu, C.; Grody, W.W.; et al. DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study. Genet. Mol. Biol. 2011, 34, 837–910. [CrossRef] [PubMed]
6. Otandault, A.; Anker, P.; Al Amir Dache, Z.; Guillaumon, V.; Meddeb, R.; Pastor, B.; Pisareva, E.; Sanchez, C.; Tanos, R.; Tousch, G.; et al. Recent advances in circulating nucleic acids in oncology. Ann. Oncol. 2019, 30, 374–384. [CrossRef] [PubMed]
7. De Rubis, G.; Rajeev Krishnan, S.; Bebawy, M. Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis. Trends Pharmacol. Sci. 2019, 40, 172–186. [CrossRef] [PubMed]
8. Van Niel, G.; D’Angelo, G.; Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 2018, 19, 213–228. [CrossRef] [PubMed]
9. Arroyo, J.D.; Chevillet, J.R.; Kroh, E.M.; Ruf, I.K.; Pritchard, C.C.; Gibson, D.F.; Mitchel, P.S.; Bennett, C.F.; Pogosova-Agadjanyan, E.L.; Stirewalt, D.L.; et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. USA 2011, 108, 5003–5008. [CrossRef] [PubMed]
10. Biró, O.; Fóthi, A.; Alasztics, B.; Nagy, B.; Orbán, T.; Rigó, J., Jr. Circulating exosomal and Argonaute-bound microRNAs in preeclampsia. Gene 2019, 692, 138–144. [CrossRef] [PubMed]
11. Zhang, X.; Hong, R.; Chen, W.; Xu, M.; Wang, L. The role of long noncoding RNA in major human disease. Bioorg. Chem. 2019, 92, 103214. [CrossRef] [PubMed]
12. Bach, D.H.; Lee, S.K.; Sood, A.K. Circular RNAs in Cancer. Mol. Ther. Nucleic Acids 2019, 16, 118–129. [CrossRef] [PubMed]
13. Yang, Z.; Xie, L.; Han, L.; Qu, X.; Yang, Y.; Zhang, Y.; He, Z.; Wang, Y.; Li, J. Circular RNAs: Regulators of Cancer-Related Signaling Pathways and Potential Diagnostic Biomarkers for Human Cancers. Theranostics 2017, 7, 3106–3117. [CrossRef] [PubMed]
14. Su, H.; Lin, F.; Deng, X.; Shen, L.; Fang, Y.; Fei, Z.; Zhao, L.; Zhang, X.; Pan, H.; Xie, D.; et al. Profiling and bioinformatics analyses reveal differential circular RNA expression in radioresistant esophageal cancer cells. J. Transl. Med. 2016, 14, 225. [CrossRef] [PubMed]
15. Lin, X.; Chen, Y. Identification of Potentially Functional CircRNA-miRNA-mRNA Regulatory Network in Hepatocellular Carcinoma by Integrated Microarray Analysis. Med. Sci. Monit. Basic Res. 2018, 24, 70–78. [CrossRef] [PubMed]
16. Nagy, B. 20th anniversary—Department of Human Genetics, Faculty of Medicine, University of Debrecen—Current states and prospects of human genetics in Central-Eastern Europe. J. Biotechnol. 2019, 301, 1. [CrossRef] [PubMed]
17. Soltesz, B.; Urbancsek, R.; Pocs, O.; Hajas, O.; Forgacs, L.N.; Szilagyi, E.; Nagy-Balos, E.; Szemes, T.; Csanadi, Z.; Nagy, B. Quantification of peripheral whole blood, cell-free plasma and exosome encapsulated mitochondrial DNA copy numbers in patients with atrial fibrillation. *J. Biotechnol.* 2019, 299, 66–71. [CrossRef] [PubMed]

18. Klekner, A.; Szivos, L.; Virga, J.; Arkozy, P.; Bognar, L.; Birko, Z.; Nagy, B. Significance of liquid biopsy in glioblastoma—A review. *J. Biotechnol.* 2019, 298, 82–87. [CrossRef] [PubMed]

19. Marton, E.; Lukacs, J.; Penyige, A.; Janka, E.; Hegedus, L.; Soltesz, B.; Mehes, G.; Poka, R.; Nagy, B.; Szilagyi, M. Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer. *J. Biotechnol.* 2019, 297, 58–65. [CrossRef] [PubMed]

20. Pocs, O.; Budis, J.; Kubiritova, Z.; Kucharik, M.; Duris, F.; Radvanszky, J.; Szemes, T. Identification of Structural Variation from NGS-Based Non-Invasive Prenatal Testing. *Int. J. Mol. Sci.* 2019, 20, 4403. [CrossRef] [PubMed]

21. Gazdarica, J.; Hekel, R.; Budis, J.; Kucharik, M.; Duris, F.; Radvanszky, J.; Turna, J.; Szemes, T. Combination of Fetal Fraction Estimators Based on Fragment Lengths and Fragment Counts in Non-Invasive Prenatal Testing. *Int. J. Mol. Sci.* 2019, 20, 3959. [CrossRef] [PubMed]

22. Gazdarica, J.; Budis, J.; Duris, F.; Turna, J.; Szemes, T. Adaptable Model Parameters in Non-Invasive Prenatal Testing Lead to More Stable Predictions. *Int. J. Mol. Sci.* 2019, 20, 3414. [CrossRef] [PubMed]

23. Hromadnikova, I.; Dvorakova, L.; Kotlabova, K.; Krofta, L. The Prediction of Gestational Hypertension, Preecclampsia and Fetal Growth Restriction via the First Trimester Screening of Plasma Exosomal C19MC microRNAs. *Int. J. Mol. Sci.* 2019, 20, 2972. [CrossRef] [PubMed]

24. Timofeeva, A.V.; Chagovets, V.V.; Drapkina, Y.S.; Makarova, N.P.; Kalinina, E.A.; Sukhikh, G.T. Cell-Free, Embryo-Specific sncRNA as a Molecular Biological Bridge between Patient Fertility and IVF Efficiency. *Int. J. Mol. Sci.* 2019, 20, 2912. [CrossRef] [PubMed]

25. Penyige, A.; Marton, É.; Soltesz, B.; Szilagyi-Bönizs, M.; Poka, R.; Lukacs, J.; Széles, L.; Nagy, B. Circulating miRNA Profiling in Plasma Samples of Ovarian Cancer Patients. *Int. J. Mol. Sci.* 2019, 20, 4533. [CrossRef] [PubMed]

26. Dvorská, D.; Braný, D.; Nagy, B.; Grendár, M.; Pora, R.; Soltesz, B.; Jagelková, M.; Zelinová, K.; Lasabová, Z.; Zubor, P.; et al. Aberrant Methylation Status of Tumour Suppressor Genes in Ovarian Cancer Tissue and Paired Plasma Samples. *Int. J. Mol. Sci.* 2019, 20, 4119.

27. Zubor, P.; Kubatká, P.; Kajo, K.; Dankova, Z.; Polacek, H.; Bielik, T.; Kudela, E.; Samec, M.; Liskova, A.; Vlakova, D.; et al. Why the Gold Standard Approach by Mammography Demands Extension by Multiomics? Application of Liquid Biopsy miRNA Profiles to Breast Cancer Disease Management. *Int. J. Mol. Sci.* 2019, 20, 2878. [CrossRef] [PubMed]

28. Konečná, B.; Töthová, L.; Repíská, G. Exosomes-Associated DNA-New Marker in Pregnancy Complications? *Int. J. Mol. Sci.* 2019, 20, 2890. [CrossRef] [PubMed]

29. Kubiritova, Z.; Jan Radvanszky, J.; Gardlik, R. Cell-Free Nucleic Acids and their Emerging Role in the Pathogenesis and Clinical Management of Inflammatory Bowel Disease. *Int. J. Mol. Sci.* 2019, 20, 3662. [CrossRef] [PubMed]

30. Dvorská, D.; Škovieronová, H.; Braný, D.; Halašová, E.; Danková, Z. Liquid Biopsy as a Tool for Differentiation of Leiomyomas and Sarcomas of Corpus Uteri. *Int. J. Mol. Sci.* 2019, 20, 3825. [CrossRef] [PubMed]

31. Andrikovics, H.; Orfi, Z.; Meggyesi, N.; Bors, A.; Varga, L.; Köváry, P.; Vilimszky, Z.; Kolics, F.; Gopcsa, L.; Reményi, P.; et al. Current Trends in Applications of Circulatory Microchimerism Detection in Transplantation. *Int. J. Mol. Sci.* 2019, 20, 4450. [CrossRef] [PubMed]

32. Janovičová, L.; Konečná, B.; Vokálová, L.; Lauková, L.; Vlková, B.; Celec, P. Sex, Age, and Bodyweight as Determinants of Extracellular DNA in the Plasma of Mice: A Cross-Sectional Study. *Int. J. Mol. Sci.* 2019, 20, 4163. [CrossRef] [PubMed]

© 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).